Mankind Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.79×	0.84×	0.80×	0.81×	0.79×
	0.90×	0.85×	1.04×	1.12×	1.05×
	20.6%	19.1%	19.6%	20.7%	18.0%
	0.51×	0.51×	0.61×	0.95×	0.93×
	1.62×	1.70×	1.91×	1.25×	1.27×
	12.2%	11.7%	19.1%	22.3%	17.7%
	12.5%	12.5%	16.8%	22.8%	18.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANKIND₹2,207.90

Mankind Pharma Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA CIPLA TORNTPHARM LAURUSLABS BIOCON ALKEM LUPIN GLENMARKMcap ₹91,142 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.79	0.81	0.80	0.84	0.79
Interest Burden (Pretax/EBIT) ×	1.05	1.12	1.04	0.85	0.90
EBIT Margin %	18.00	20.68	19.63	19.13	20.61
Asset Turnover ×	0.93	0.95	0.61	0.51	0.51
Financial Leverage (Assets/Equity) ×	1.27	1.25	1.91	1.70	1.62
ROE (5-step product, year-end total equity) %	17.74	22.30	19.15	11.74	12.17
ROE (owners' profit / average owners' equity) %	18.86	22.77	16.77	12.49	12.49

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.